Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer

Polish Journal of Pathology

Volumn 63, Issue 4, 2012, Pages 272-277

  Luczynska, Elzbieta ^a   Gasinska, Anna ^a   Wilk, Waclaw ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

GLUT 1; Immunohistochemistry; Ki 67; MIB 1; Prostatic cancer

Indexed keywords

GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BLOOD; CANCER GRADING; CANCER STAGING; CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY;

CARCINOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873859053     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2012.32480     Document Type: Article

References (27)

1. Revelos K, Petraki C, Gregorakis A, et al. p27 kip1 and Ki-67 (MIB) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 2005; 19: 911-920.
2. Killick E, Bancroft E, Kote-Jarai Z, Eeles R. Beyond Prostatespecific Antigen - future biomarkers for the early detection and management of prostate cancer. Clin Oncol 2012: 24: 545-555.
3. Goto T, Nguyen BP, Nakano M, et al. Utility of Bcl-2, P53, Ki-67, and Caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology 2008; 72: 167-171.
4. Cowen D, Troncoso P, Khoo VS, et al. Ki-67 is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002; 8: 1148-1154.
5. Malhotra S, Lapointe J, Salari K, et al. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. Plos ONE 2011; 6: 1-7.
6. Inoue T, Segawa T, Shiraishi T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332-337.
7. Vis AN, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27 (kip) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000; 164: 2156-2161.
8. Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localized prostate cancer: analysis of conservatively treated prostate cancer patients from Trans-Atlantic Prostate Group study. Brit J Cancer 2009; 1000: 888-893.
9. Nagao K, Yamamoto Y, Hara T, et al. Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range < 4 ng/ml. Jpn J Clin Oncol 2011; 41: 555-564.
10. Zellweger T, Gunther S, Zlobec I, et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009; 124: 2116-2123.
11. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998; 82: 168-175.
12. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-662.
13. Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anatomy 2010; 192: 133-138.
14. Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut- 1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7: 928-934.
15. Effert P, Beniers AJ, Tamimi Y, et al. Expression of Glucose Transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res 2004; 24: 3057-3064.
16. Chandler JD, Williams ED, Slavin JL, et al. Expression and localization of GLUT-1 and GLUT12 in prostate carcinoma. Cancer 2003; 97: 2035-2042.
17. Stewart GD, Gray K, Pennington CJ, et al. Analysis of hypoxiaassociated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncology Rep 2008; 20: 1561-1567.
18. AJCC Cancer Staging Manual. Edge SB, Byrd DR, Compton CC, et al. (eds). Springer, New York - Dordrecht - Heidelberg - London 2010; 457-464.
19. Gleason DF. The Veterans Administration Cooperative Urological Research Group: histological grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The prostate. Tannenbaum M (ed.). Lea and Febiger, Philadelphia 1997; 171-197.
20. Lopez-Beltran A, Cheng L, Blanca A, Montironi R. Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7. Anal Quant Cytol Histol 2012; 34: 61-65.
21. Liu Y, Vlatkovic L, Saeter T, et al. Is the clinical malignant phenotype of prostate cancer a result of highly proliferative immuneevasive B7-H3-expressing cell population? Int J Urol 2012; 19: 749-756.
22. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007; 7: 591-604.
23. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
24. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27: 441-464.
25. Reinicke K, Sotomayor P, Cisterna P, et al. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Bioch 2012; 113: 553-562.
26. Hoskin PJ, Sibtain A, Daley FM, et al. The immunohistochemical assessment of hypoxia, vasculaity and proliferation in bladder carcinoma. Radiother Oncol 2004; 72: 159-168.
27. Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol 1000; 180: 431-438.